Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Whitepapers & Reports

Validation of a Structure-Function Assay for Neurotoxicity in Primary and hiPSC-Derived Neurons

09 June 2022
Comprehensive, high-throughput, in vitro screening of the neurological effects of chemical compounds and drugs is vital for environmental and drug safety
Open document in a new tab

Related Resources

Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years

According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults.
Read More

Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments

Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles.
Read More